ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP

被引：0

作者：

Besse, Benjamin ^{[1
]}

Mazieres, Julien ^{[2
]}

Ribassin-Majed, L. ^{[3
]}

Barlesi, Fabrice ^{[4
]}

Bennouna, Jaafar ^{[5
]}

Gervais, Radj ^{[6
]}

Moreau, Lionel

Berard, Henri ^{[7
]}

Debieuvre, Didier

Molinier, Olivier ^{[8
]}

Moro-Sibilot, Denis ^{[9
]}

Souquet, Pierre-Jean ^{[10
]}

Pignon, Jean-Pierre ^{[3
]}

Amour, Elodie ^{[11
]}

Celebic, A. ^{[3
]}

Morin, Franck ^{[11
]}

Milleron, Bernard ^{[11
]}

Zalcman, Gerard ^{[12
]}

Soria, Jean-Charles ^{[1
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Univ Toulouse 3, Resp Med Serv, Hop Larrey, Chu Toulouse, F-31062 Toulouse, France

[3] Gustave Roussy, Biostat, Villejuif, France

[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France

[5] Inst Cancerol Ouest, Gustave Roussy, France

[6] Ctr Francois Baclesse, Caen, France

[7] Hop Instruct Armees St Anne, Serv Pathol Resp, Toulon, France

[8] Le Mans Reg Hosp, Le Mans, France

[9] Unite Oncol Thorac Pneumol, Pierre Benite, France

[10] Pneumol Hcl, Paris, France

[11] Ifct, Paris, France

[12] Caen Univ Hosp, Caen, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

adjuvant; Non small cell lung cancer; angiogenic inhibitor; randomized phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO08.02

引用

页码：S301 / S301

页数：1

共 39 条

[1] Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
Besse, B.
Mazieres, J.
Ribassin-Majed, L.
Barlesi, F.
Bennouna, J.
Gervais, R.
Moreau, L.
Berard, H.
Debieuvre, D.
Molinier, O.
Moro-Sibilot, D.
Souquet, P. J.
Jacquot, S.
Petit, L.
Lena, H.
Pignon, J. P.
Lacas, B.
Morin, F.
Milleron, B.
Zalcman, G.
Soria, J. C.
ANNALS OF ONCOLOGY, 2017, 28 (05) : 1078 - 1083
[2] A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation after Curative Resection for Stage I NSCLC with Primary Tumors Between 1-4 cm
Durm, G.
Birdas, T.
Liu, H.
Jalal, S.
Kesler, K.
Rieger, K.
Ceppa, D.
Hanna, N.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S257 - S258
[3] TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC
Soo, R.
De Marinis, F.
Han, J. -Y.
Ho, C. M. J.
Lin, Y.
Servidio, L.
Sandelin, M.
Popat, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S272 - S272
[4] Randomized Ph II Trial of Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC
Sanborn, Rachel
Boulmay, Brian
Li, Rui
Happel, Kyle
Puri, Sachin
Paustian, Christopher
Dubay, Christopher
Aung, Sandra
Fisher, Brenda
Bifulco, Carlo
Bahjat, Keith
Koguchi, Yoshinobu
Ochoa, Augusto
Hu, Hong-Ming
Hilton, Traci
Fox, Bernard
Urbal, Walter
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S873 - S873
[5] Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
Kreuter, M.
Vansteenkiste, J.
Fischer, J. R.
Eberhardt, W.
Zabeck, H.
Kollmeier, J.
Serke, M.
Frickhofen, N.
Reck, M.
Engel-Riedel, W.
Neumann, S.
Thomeer, M.
Schumann, C.
De Leyn, P.
Graeter, T.
Stamatis, G.
Zuna, I.
Griesinger, F.
Thomas, M.
ANNALS OF ONCOLOGY, 2013, 24 (04) : 986 - 992
[6] Randomized ph II Trial of Cyclophosphamide with Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC
Sanborn, Rachel E.
Boulmay, Brian
Li, Rui
Happel, Kyle T.
Ross, Helen J.
Puri, Sachin
Paustian, Christopher
Dubay, Christopher
Hoen, Helena
Aung, Sandra
Fisher, Brenda
Bifulco, Carlo
Bahjat, Keith
Ochoa, Augusto C.
Hu, Hong-Ming
Hilton, Traci L.
Fox, Bernard A.
Urba, Walter J.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S684 - S684
[7] Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
Gross-Goupil, M.
Kwon, T. G.
Eto, M.
Ye, D.
Miyake, H.
Seo, S. I.
Byun, S-S
Lee, J. L.
Master, V.
Jin, J.
DeBenedetto, R.
Linke, R.
Casey, M.
Rosbrook, B.
Lechuga, M.
Valota, O.
Grande, E.
Quinn, D. I.
ANNALS OF ONCOLOGY, 2018, 29 (12) : 2371 - 2378
[8] Three-Year Safety, Tolerability, and Health- Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
John, Thomas
Grohe, Christian
Goldman, Jonathan W.
Shepherd, Frances A.
de Marinis, Filippo
Kato, Terufumi
Wang, Qun
Su, Wu-Chou
Choi, Jin Hyuk
Sriuranpong, Virote
Melotti, Barbara
Fidler, Mary J.
Chen, Jun
Albayaty, Muna
Stachowiak, Marta
Taggart, Sarah
Wu, Yi-Long
Tsuboi, Masahiro
Herbst, Roy S.
Majem, Margarita
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : 1209 - 1221
[9] A phase III randomized trial of postoperative adjuvant therapy in Stage II or IIIA completely resected non-small cell lung cancer
Yoon, S
Choi, E
Kim, S
Suh, C
Lee, J
Shim, T
Kim, W
Kim, D
Park, S
Park, C
LUNG CANCER, 2005, 49 : S288 - S288
[10] Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)
Kreuter, Michael
Vansteenkiste, Johan
Fischer, Juergen R.
Eberhardt, Wilfried E.
Zabeck, Heike
Kollmeier, Jens
Serke, Monika
Frickhofen, Norbert
Reck, Martin
Engel-Riedel, Walburga
Neumann, Silke
Thomeer, Michiel
Schumann, Christian
De Leyn, Paul
Graeter, Thomas
Stamatis, Georgios
Griesinger, Frank
Thomas, Michael
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) : 85 - 93

← 1 2 3 4 →